These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 12215911)

  • 1. [Onset of action of formoterol in patients with moderate to severe, partially reversible airflow obstruction assessed by bodyplethysmography].
    Beier J; Beeh KM; Tröger K; Stenglein S; Bräutigam M; Buhl R; Schmidt EW
    Pneumologie; 2002 Sep; 56(9):535-41. PubMed ID: 12215911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.
    Richter K; Stenglein S; Mücke M; Sieder C; Schmidtmann S; Harnest U; Weidinger G; Magnussen H
    Respiration; 2006; 73(4):414-9. PubMed ID: 16534180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G; Kayacan O; Beder S; Durmaz G
    Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
    Aalbers R; Brusselle G; McIver T; Grothe B; Bodzenta-Lukaszyk A
    Adv Ther; 2012 Nov; 29(11):958-69. PubMed ID: 23081745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma].
    Sill V; Bartuschka B; Villiger B; Ortland C; Domej W
    Pneumologie; 1999 Jan; 53(1):4-9. PubMed ID: 10091511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S; Eberlein M; Eckhoff J; Schirren J
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.
    Berger WE; Nadel JA
    Respir Med; 2008 Feb; 102(2):173-88. PubMed ID: 18023995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
    Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
    Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
    Campbell M; Eliraz A; Johansson G; Tornling G; Nihlén U; Bengtsson T; Rabe KF
    Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.
    Di Marco F; Verga M; Santus P; Morelli N; Cazzola M; Centanni S
    Respir Med; 2006 Nov; 100(11):1925-32. PubMed ID: 16626956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
    Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
    COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F
    Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
    Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
    Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
    Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
    Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
    Papi A; Paggiaro P; Nicolini G; Vignola AM; Fabbri LM;
    Allergy; 2007 Oct; 62(10):1182-8. PubMed ID: 17845589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.